Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exporti… Read more
Karyopharm Therapeutics Inc (KPTI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.022x
Based on the latest financial reports, Karyopharm Therapeutics Inc (KPTI) has a cash flow conversion efficiency ratio of 0.022x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.86 Million) by net assets ($-269.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Karyopharm Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Karyopharm Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Karyopharm Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Karyopharm Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Acres Commercial Realty Corp
NYSE:ACR
|
-0.022x |
|
Prime Mining Corp
OTCQX:PRMNF
|
-0.048x |
|
Priner Serviços Industriais S.A
SA:PRNR3
|
0.056x |
|
Nabors Energy Transition Corp. II Class A Ordinary Shares
NASDAQ:NETD
|
-0.004x |
|
Genome & Company
KQ:314130
|
-0.065x |
|
1Stdibs.Com Inc
NASDAQ:DIBS
|
0.046x |
|
SIMILARWEB LTD IS-01
F:63X
|
N/A |
|
Garofalo Health Care S.p.A
F:GHC
|
0.060x |
Annual Cash Flow Conversion Efficiency for Karyopharm Therapeutics Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Karyopharm Therapeutics Inc from 2011 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-292.93 Million | $-75.37 Million | 0.257x | -62.46% |
| 2024-12-31 | $-186.02 Million | $-127.49 Million | 0.685x | +0.67% |
| 2023-12-31 | $-136.21 Million | $-92.72 Million | 0.681x | -92.42% |
| 2022-12-31 | $-16.66 Million | $-149.55 Million | 8.979x | +567.86% |
| 2021-12-31 | $-79.67 Million | $-107.12 Million | 1.344x | +142.41% |
| 2020-12-31 | $50.55 Million | $-160.23 Million | -3.170x | +17.31% |
| 2019-12-31 | $49.77 Million | $-190.82 Million | -3.834x | -341.33% |
| 2018-12-31 | $183.17 Million | $-159.12 Million | -0.869x | -52.56% |
| 2017-12-31 | $129.46 Million | $-73.72 Million | -0.569x | -9.47% |
| 2016-12-31 | $162.24 Million | $-84.39 Million | -0.520x | -9.73% |
| 2015-12-31 | $198.37 Million | $-94.03 Million | -0.474x | -90.53% |
| 2014-12-31 | $206.79 Million | $-51.45 Million | -0.249x | -27.25% |
| 2013-12-31 | $154.93 Million | $-30.29 Million | -0.196x | -135.14% |
| 2012-12-31 | $-27.88 Million | $-15.51 Million | 0.556x | -17.67% |
| 2011-12-31 | $-12.65 Million | $-8.55 Million | 0.676x | -- |